Bowel cleaning versus no bowel cleaning before laparoscopic right colectomy with internal (intracorporeal) anastomosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center randomized trial at University Medical Center Ho Chi Minh City assigns eligible patients to either receive mechanical bowel preparation (MBP) or not before elective laparoscopic right hemicolectomy with totally intracorporeal anastomosis using a web-based minimization algorithm. The primary endpoint is surgical site infection within 30 days after surgery, and secondary endpoints include intraoperative contamination, anastomotic leakage, postoperative ileus, operative time, and recovery metrics. Patients with stage I–III colon adenocarcinoma undergoing elective curative surgery are enrolled, while those with emergency surgery, stage IV disease, or contraindications to MBP are excluded. The trial aims to clarify whether MBP meaningfully alters intraoperative contamination and short-term postoperative outcomes in the intracorporeal anastomosis setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with colon cancer stage I-III according to the TNM classification
* Patients undergoing elective right hemicolectomy or extended right hemicolectomy with totally intracorporeal anastomosis at University Medical Center Ho Chi Minh City
* Postoperative histopathological confirmation of adenocarcinoma

Exclusion Criteria:

* Patients undergoing emergency surgery
* Contraindications to mechanical bowel preparation (e.g., bowel obstruction, subobstruction, bowel perforation, or peritumoral abscess)
* Contraindications to laparoscopic surgery (American Society of Anesthesiologists \[ASA\] physical status IV or V) or to intracorporeal anastomosis
* Distant metastasis at the time of surgery (stage IV according to the TNM classification)
* Recurrent colon cancer after prior surgery
* Synchronous primary malignancies in other organs
* Patients undergoing palliative surgery or surgery for tumor-related complications (non-curative intent)
* Inability to complete follow-up or be contacted

Where it's running

• University Medical Center HCMC
  Ho Chi Minh City, Ho Chi Minh, Vietnam Recruiting

Study contacts

• Principal investigator: Tran D Huy, PhD, MD — University medical center HCMC
• Study coordinator: Tran D Huy, PhD, MD
• Email: huy.td@umc.edu.vn
• Phone: +84909873773

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

• ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer

  This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07841236

• Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer

  This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07840677

• Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer

  This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.

  Recruiting at 3 sites Phase 2 Solstice Oncology, Inc. · Los Angeles, California and 29 other locations · NCT07808151

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.